Clin Rheumatol. 2024 Dec 20. doi: 10.1007/s10067-024-07268-w. Online ahead of print.
ABSTRACT
OBJECTIVE: To develop and validate prediction models for estimating the activity index (AI) of kidney histopathology in lupus nephritis (LN) using clinical and laboratory data.
METHODS: This study used single-center data from patients with kidney biopsy-confirmed LN between January 2012 and March 2022. The development and validation datasets were temporally cut. We discriminated AI > 10 and ≤ 10 as high and mild/moderate activity status, respectively. We constructed four models for AI: Model 1 included demographic information; Model 2 additionally incorporated data of systemic conditions; Model 3 further included kidney-specific conditions; and Model 4 included all the aforementioned predictors. Logistic regression was employed in Models 1 to 3, while Model 4 utilized least absolute shrinkage and selection operator for predictor selection and model building. Internal validation was performed using 1000 bootstrap resampling, while external validation was performed in the temporal validation dataset. Both calibration and discrimination metrics were evaluated.
RESULTS: There were 160 patients in the development dataset and 70 patients in the validation dataset. In the temporal validation, all the models achieved acceptable calibration and excellent discrimination. Model 2 which contained relatively fewer predictors achieved the highest area under the receiver operator characteristic curve of 0.86 (95% confidence interval 0.76 to 0.94).
CONCLUSION: Our Model 2 incorporating demographic and systemic indicators exhibited good performance in estimating the AI of LN. We thus provide a simple yet effective algorithm to predict AI in patients with LN, potentially aiding clinicians in non-invasively assessing disease activity and guiding treatment decisions. Key Points • We developed a prediction model (Model 2) incorporating demographic and systemic indicators to predict AI in patients with LN. • The prediction model can aid clinicians in noninvasively assessing disease activity and guiding treatment decisions.
PMID:39704985 | DOI:10.1007/s10067-024-07268-w
